KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Free Cash Flow readings, the most recent being $293.0 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 6250.67% to $293.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $346.8 million, a 766.59% increase, with the full-year FY2025 number at $346.8 million, up 766.59% from a year prior.
  • Free Cash Flow hit $293.0 million in Q4 2025 for Biocryst Pharmaceuticals, up from $41.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $293.0 million in Q4 2025 to a low of -$78.2 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$24.0 million (2021), compared with a mean of -$5.4 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 161.19% in 2021 and later surged 6250.67% in 2025.
  • Biocryst Pharmaceuticals' Free Cash Flow stood at -$33.6 million in 2021, then grew by 27.38% to -$24.4 million in 2022, then skyrocketed by 70.03% to -$7.3 million in 2023, then surged by 34.78% to -$4.8 million in 2024, then surged by 6250.67% to $293.0 million in 2025.
  • The last three reported values for Free Cash Flow were $293.0 million (Q4 2025), $41.0 million (Q3 2025), and $40.4 million (Q2 2025) per Business Quant data.